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Conclusion: these favorable results in large volume liver 
metastases from low grade NET, although derived from only 
two anedoctal cases, give support to the concept that the 
outcome of SBRT is relatively independent from tumor type, 
being mainly mediated by an ablative effect. Also they 
represent a typical example showing how repeat liver SBRT 
may lead to a a significant delay in disease progression 
although without achieving a definitive cure. 
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Purpose or Objective: To review stereotactic body radiation 
therapy (SBRT) safety and local control utility in malignant 
tumor of the pancreas based in a single center experience 
since February 2014. 
 
Material and Methods: A systematic review was done. 
Thirteen patients were treated with SBRT. Eleven patients 
had a primary pancreatic tumor and two patients had 
metastatic affectation of the pancreas. In those patients with 
primary pancreatic cancer, four patients were treated with a 
radical intent, five as a part of a neoadjuvant treatment and 
four patients with a palliative intent. All of the treated 
tumors had a diameter bigger than 2 cm. At least 2 fiducials 
were located into the tumor, guided by endoscopic 
ultrasound. All the treatments included CT or PET-CT for GTV 
delineation, intensity-modulated radiation therapy (IMRT) 
and image-guided radiation therapy (IGRT) with intrafraction 
control of tumor motion with a Novalis Exactrac Adaptive 
Gating System. 50 Gy in 10 fractions were prescribed in 
eleven patient, one patient was treated with 35Gy in 5 
fractions and one patient was treated with 40Gy in 10 
fraction. 
 
Results: Pancreatic SBRT was very well tolerated in our 
cohort of patients. No grade 3 or higher toxicity was 
observed. Only 3 patients developed grade 2 epigastric pain 
and/or grade 2 nausea/vomiting. The median patient age was 
62 years old (range 36 – 86 years) and the median follow-up 
was 14 months (range 2 – 18 months). Five patients under 
went surgery after SBRT. The median overall survival was 
14.5 months (range 2.4 – 18.2 months), with 65.3% survival at 
one year. Median survival time is 15 month (range 12 – 17 
months). Median time to local progression has not been 
reached. 
 
Conclusion: In our experience, gating SBRT for pancreatic 
tumor is a well-tolerated feasible treatment. Most patients 
are free from local progression, but overall survival remains 
poor. Prospective studies are needed to define the role of 
SBRT for pancreatic tumors. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
in pancreatic cancer can be limited by its proximity to 
critical organs at risk (OAR) of the upper abdomen. In this 
study we evaluate the toxicity and efficacy of two different 
treatment approaches. 
 
Material and Methods: Patients with recurrent or 
oligometastatic pancreas cancer were treated with SBRT. The 
planning target volume (PTV) was created through a 4 mm 
expansion of the internal target volume (ITV) based on a four 
dimensional CT (4D-CT). All patients were treated with 
intensity modulated radiation therapy (IMRT). In some cases 
we created a sub-volume, in order to reduce the risk of 
toxicity in critical adjacent OARs without compensating the 
whole PTV. This sub-volume was defined as a simultaneous 
integrated protection (SIP) PTV. The SIP consisted of the 
interface of the PTV with the planning risk volume (PRV) of a 
specific vulnerable structure at which we prescribed a pre-
defined reduced dose. 
 
Results: Between 2009 and 2014, 18 patients with 23 lesions 
were treated in our institution. Seven patients were treated 
for a local recurrence, nine were treated for oligometastases 
(liver, lymph nodes) and two patients were treated for both. 
Of these lesions 11 were treated with SIP and 12 were 
treated without SIP. The median follow up was 10.8 months 
(range 1.2-40.3 months). The freedom from local progression 
(FFLP) at 6 and 12 months was 90% and 84% respectively. The 
overall survival (OS) rates at 6 months and 12 months after 
SBRT were 77% and 54%, respectively. Two patients (11%) 
experienced grade >3 acute toxicity (mechanical ileus, 
gastrointestinal bleeding) and 2 patients (11%) experienced a 
grade > 3 late toxicity (cholangitis, bleeding). 
 
Conclusion: Local control and overall survival after SBRT in 
this high risk group of patients with pancreatic cancer were 
excellent despite of dose sacrifice in half of the patients 
when OARs were close to the PTV, with overall favourable 
toxicity. 
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Purpose or Objective: To evaluate the efficacy and 
feasibility of stereotactic ablative radiotherapy (SABR) in the 
treatment of liver metastases. 
 
Material and Methods: We retrospectively analyzed patients 
with 1-2 secondary liver lesions treated with SABR. The total 
dose prescriptions were 30 Gy, 37.5 Gy and 45 Gy on three 
consecutive days in 42.8%, 22.8% and 34.4% of patients 
respectively. The dose was prescribed to the 80% isodose line 
covering the PTV. The primary endpoints were in field local 
control and toxicity; the secondary endpoint was survival 
rates. 
 
Results: Between March 2007 and May 2015, 30 patients (17 
males, 13 females) with 36 liver metastases were treated. 
The mean age was 66 years (range, 40-90 years). Twenty-five 
patients (83.3%) had a single hepatic lesion and the 
remaining 5 patients (16.7%) two hepatic lesions. Twenty 
patients (64.5%) had extrahepatic stable disease. The most 
frequent sites of primary tumor were colorectal (58%) and 
breast (20%). The majority of the lesions treated (75.6%) had 
a diameter of less than 3 cm. With a median follow-up of 21 
months (range 2.3-69.8 months) for all patients, “in field” 
local response rate was 90%. No patient developed a toxicity 
greater than grade 2 according to CTC scale v4.02 and no 
radio-induced liver disease (RILD) was recorded. One-year LC 
and two-year LC were 62% and 39% respectively. One-year 
and two-year PFS were 46% and 25% (median, 11 months). 
One-year, two-year and three-year OS were 89%, 69 and 42% 
